From GlobeNewswire: 2025-04-08 16:00:00

Nurix Therapeutics, Inc. announced the nonproprietary name “bexobrutideg” for NX-5948, with FDA Orphan Drug Designation for Waldenström macroglobulinemia. They achieved $7M in milestones and $15M license extension fee from Sanofi, appointed Roy D. Baynes to the Board, and added John Northcott as chief commercial officer. They have $549.7 million in cash and marketable securities.

The company reported strong financial results for the fiscal quarter ended February 28, 2025. CEO Arthur T. Sands highlighted key achievements, including collaboration milestones and leadership additions. Nurix plans to start pivotal trials for bexobrutideg in 2025 for chronic lymphocytic leukemia and continue work on degrader-based drugs for autoimmune disease and inflammation.

Bexobrutideg, formerly NX-5948, was granted U.S. FDA Orphan Drug designation for Waldenström macroglobulinemia. Dr. Roy D. Baynes joined the board and John Northcott became chief commercial officer. Nurix aims to advance clinical trials for bexobrutideg and other programs, including potential treatments for autoimmune and inflammatory diseases.

Financially, Nurix reported revenue of $18.5 million for the quarter ended February 28, 2025, with $69.7 million in research and development expenses. The net loss for the quarter was $56.4 million. The company had $549.7 million in cash and marketable securities as of February 28, 2025, excluding recent milestones earned and payments received.

Looking ahead, Nurix plans to initiate pivotal trials for bexobrutideg, targeting CLL, and explore treatments for autoimmune and inflammatory diseases. They are conducting trials on degraders of BTK and cereblon neosubstrates, with future updates expected in 2025. Nurix also has programs with partners like Gilead, Sanofi, and Pfizer for continued pipeline advancement.



Read more at GlobeNewswire:: Nurix Therapeutics Reports First Quarter 2025 Financial